Population Pharmacokinetics of Losmapimod in Healthy Subjects and Patients with Rheumatoid Arthritis and Chronic Obstructive Pulmonary Diseases

被引：0
|
作者：
Shuying Yang
Pauline Lukey
Misba Beerahee
Frank Hoke
机构：
[1] Quantitative Sciences,Clinical Pharmacology Modelling and Simulation
[2] GlaxoSmithKline,Clinical Pharmacology Modelling and Simulation
[3] Fibrosis Discovery Performance Unit,Clinical Pharmacology Modelling and Simulation
[4] GlaxoSmithKline,undefined
[5] Quantitative Sciences,undefined
[6] GlaxoSmithKline,undefined
[7] Quantitative Sciences,undefined
[8] GlaxoSmithKline,undefined
来源：
Clinical Pharmacokinetics | 2013年 / 52卷
关键词：
Rheumatoid Arthritis; Chronic Obstructive Pulmonary Disease; Chronic Obstructive Pulmonary Disease Patient; Prediction Interval; Population Pharmacokinetic Model;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：187 / 198
页数：11
相关论文
共 50 条
  • [1] Population Pharmacokinetics of Losmapimod in Healthy Subjects and Patients with Rheumatoid Arthritis and Chronic Obstructive Pulmonary Diseases
    Yang, Shuying
    Lukey, Pauline
    Beerahee, Misba
    Hoke, Frank
    CLINICAL PHARMACOKINETICS, 2013, 52 (03) : 187 - 198
  • [2] Integrated Population Pharmacokinetics of Etanercept in Healthy Subjects and in Patients With Rheumatoid Arthritis and Ankylosing Spondylitis
    Zhou, Simon Y.
    Shu, Cathye
    Korth-Bradley, Joan
    Raible, Donald
    Palmisano, Maria
    Wadjula, Joseph
    Fatenejad, Saeed
    Bjornsson, Thorir
    JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 51 (06): : 864 - 875
  • [3] Rheumatoid arthritis and comorbid chronic obstructive or interstitial pulmonary diseases: Prevalence in a population-based cohort
    Mapel, Douglas
    Roberts, Melissa
    Von Worley, Ann
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [4] Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease
    Arthur Lo
    Marie T. Borin
    David L. Bourdet
    Clinical Pharmacokinetics, 2021, 60 : 391 - 401
  • [5] Population Pharmacokinetics of Revefenacin in Patients with Chronic Obstructive Pulmonary Disease
    Lo, Arthur
    Borin, Marie T.
    Bourdet, David L.
    CLINICAL PHARMACOKINETICS, 2021, 60 (03) : 391 - 401
  • [6] Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials
    Kluender, Ben
    Mohamed, Mohamed-Eslam F.
    Othman, Ahmed A.
    CLINICAL PHARMACOKINETICS, 2018, 57 (08) : 977 - 988
  • [7] Population Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects with Rheumatoid Arthritis: Analyses of Phase I and II Clinical Trials
    Ben Klünder
    Mohamed-Eslam F. Mohamed
    Ahmed A. Othman
    Clinical Pharmacokinetics, 2018, 57 : 977 - 988
  • [8] Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease
    Sarah Siederer
    Ann Allen
    Shuying Yang
    European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41 : 743 - 758
  • [9] Population Pharmacokinetics of Inhaled Fluticasone Furoate and Vilanterol in Subjects with Chronic Obstructive Pulmonary Disease
    Siederer, Sarah
    Allen, Ann
    Yang, Shuying
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2016, 41 (06) : 743 - 758
  • [10] Pharmacokinetics of Modified-Release Prednisone Tablets in Healthy Subjects and Patients With Rheumatoid Arthritis
    Derendorf, Hartmut
    Ruebsamen, Klaus
    Clarke, Lynsey
    Schaeffler, Achim
    Kirwan, John R.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (03): : 326 - 333
12345